TOR Pathway

关注
Scientist examining extended-lifespan yeast cells under microscope with rapalink-1 cancer drug vial, illustrating anti-aging breakthrough.
AI 生成的图像

Next-generation cancer drug shows anti-aging effects in yeast

由 AI 报道 AI 生成的图像 事实核查

Researchers at Queen Mary University of London have found that rapalink-1, an experimental TOR inhibitor being investigated for cancer therapy, extends the lifespan of fission yeast. The study also uncovered a role for agmatinases in regulating the TOR pathway through a metabolic feedback loop, suggesting potential links between diet, gut microbes, and aging.

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝